2024
Determination of minimum inhibitory concentrations using machine-learning-assisted agar dilution. (Journal article)
Gerada, A., Harper, N., Howard, A., Reza, N., & Hope, W. (2024). Determination of minimum inhibitory concentrations using machine-learning-assisted agar dilution.. Microbiology spectrum, e0420923. doi:10.1128/spectrum.04209-23DOI: 10.1128/spectrum.04209-23
Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing. (Journal article)
Reza, N., Gerada, A., Stott, K. E., Howard, A., Sharland, M., & Hope, W. (2024). Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.. Clinical microbiology reviews, e0013923. doi:10.1128/cmr.00139-23DOI: 10.1128/cmr.00139-23
System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework. (Journal article)
AMR-X Collaborators. (2024). System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework.. The Lancet. Microbe, S2666-5247(24)00003-X. doi:10.1016/s2666-5247(24)00003-xDOI: 10.1016/s2666-5247(24)00003-x
Farrington, N., Dubey, V., Johnson, A., Horner, I., Stevenson, A., Unsworth, J., . . . Darlow, C. A. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.. mBio, 15(2), e0316523. doi:10.1128/mbio.03165-23DOI: 10.1128/mbio.03165-23
Howard, A., Aston, S., Gerada, A., Reza, N., Bincalar, J., Mwandumba, H., . . . Buchan, I. (2024). Antimicrobial learning systems: an implementation blueprint for artificial intelligence to tackle antimicrobial resistance.. The Lancet. Digital health, 6(1), e79-e86. doi:10.1016/s2589-7500(23)00221-2DOI: 10.1016/s2589-7500(23)00221-2
Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop. (Journal article)
Howard, A., Reza, N., Aston, S., Woods, B., Gerada, A., Buchan, I., . . . Märtson, A. -G. (2024). Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop.. The Lancet. Infectious diseases, 24(1), e47-e58. doi:10.1016/s1473-3099(23)00367-5DOI: 10.1016/s1473-3099(23)00367-5
2023
Darlow, C. A., Parrott, N., Peck, R. W., & Hope, W. (2023). Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.. CPT: pharmacometrics & systems pharmacology. doi:10.1002/psp4.13097DOI: 10.1002/psp4.13097
Giamberardino, C. D., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Schell, W., Boua, J. -V. K., . . . Perfect, J. R. (2023). Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis.. Antimicrobial agents and chemotherapy, 67(10), e0081823. doi:10.1128/aac.00818-23DOI: 10.1128/aac.00818-23
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need (Journal article)
Yasinskaya, Y., Bala, S., Waack, U., Dixon, C., Higgins, K., Moore, J. N., . . . Farley, J. (2023). Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need. CLINICAL INFECTIOUS DISEASES, 77(3), 380-387. doi:10.1093/cid/ciad195DOI: 10.1093/cid/ciad195
Kempson, F., Woolley, S., Coles, Z., Kenawy, A., Muntasser, H., Ghadiri, N., . . . van Aartsen, J. J. (2023). Trichosporon inkin and Cutibacterium acnes bioprosthetic aortic valve endocarditis and prosthetic aortic root abscess with multi-focal emboli. Clinical Infection in Practice, 19, 100233. doi:10.1016/j.clinpr.2023.100233DOI: 10.1016/j.clinpr.2023.100233
ChatGPT and antimicrobial advice: the end of the consulting infection doctor? (Journal article)
Howard, A., Hope, W., & Gerada, A. (2023). ChatGPT and antimicrobial advice: the end of the consulting infection doctor?. LANCET INFECTIOUS DISEASES, 23(4), 405. doi:10.1016/S1473-3099(23)00113-5DOI: 10.1016/S1473-3099(23)00113-5
Stott, K. E., Ahmadu, A., Kajanga, C., Moyo, M., Gondwe, E., Chimang'anga, W., . . . Mwandumba, H. C. (2023). Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 78(4), 1015-1022. doi:10.1093/jac/dkad038DOI: 10.1093/jac/dkad038
Howard, A., & Hope, W. (2023). Assessment of Antifungal Pharmacodynamics. JOURNAL OF FUNGI, 9(2). doi:10.3390/jof9020192DOI: 10.3390/jof9020192
2022
Stott, K. E., Moyo, M., Ahmadu, A., Kajanga, C., Gondwe, E., Chimang'anga, W., . . . Martson, A. -G. (2023). Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 78(1), 276-283. doi:10.1093/jac/dkac389DOI: 10.1093/jac/dkac389
Giamberardino, C. D., Schell, W. A., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Marius, C., . . . Shaw, K. J. (2022). Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. MBIO, 13(6). doi:10.1128/mbio.02347-22DOI: 10.1128/mbio.02347-22
Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323DOI: 10.1093/jac/dkac323
Wilson, R. C., Arkell, P., Riezk, A., Gilchrist, M., Wheeler, G., Hope, W., . . . Rawson, T. M. (2022). Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(9), 2364-2372. doi:10.1093/jac/dkac200DOI: 10.1093/jac/dkac200
Boyd, S. E., Holmes, A., Peck, R., Livermore, D. M., & Hope, W. (2022). OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(8). doi:10.1128/aac.00216-22DOI: 10.1128/aac.00216-22
Howard, A., & Hope, W. (2022). CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy. JAC-ANTIMICROBIAL RESISTANCE, 4(4). doi:10.1093/jacamr/dlac081DOI: 10.1093/jacamr/dlac081
Darlow, C. A., & Hope, W. (2022). Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales (vol 77, pg 711, 2022). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2049. doi:10.1093/jac/dkac153DOI: 10.1093/jac/dkac153
Darlow, C. A., & Hope, W. (2022). Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' response. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2047-2048. doi:10.1093/jac/dkac072DOI: 10.1093/jac/dkac072
Darlow, C. A., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(5), 1334-1343. doi:10.1093/jac/dkac038DOI: 10.1093/jac/dkac038
Informing Antibiotic Guardianship to Combat Antimicrobial Resistance: The Liverpool Citizens’ Jury on AMR (Conference Paper)
Hope, W., Amos, J., Atwood, S., Bozentko, K., Lamb, A., Leeming, G., . . . Townsend, A. (n.d.). Informing Antibiotic Guardianship to Combat Antimicrobial Resistance: The Liverpool Citizens’ Jury on AMR. In ESPAUR 2022. MDPI. doi:10.3390/msf2022015009DOI: 10.3390/msf2022015009
Jarvis, J. N., Lawrence, D. S., Meya, D. B., Kagimu, E., Kasibante, J., Mpoza, E., . . . Harrison, T. S. (2022). Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. NEW ENGLAND JOURNAL OF MEDICINE, 386(12), 1109-1120. doi:10.1056/NEJMoa2111904DOI: 10.1056/NEJMoa2111904
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance (Journal article)
Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Darlow, C., Jimenez-Valverde, A., . . . Hope, W. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(4). doi:10.1128/aac.02181-21DOI: 10.1128/aac.02181-21
2021
Darlow, C. A., & Hope, W. (2021). Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(3), 711-718. doi:10.1093/jac/dkab468DOI: 10.1093/jac/dkab468
Maertson, A. -G., Alffenaar, J. -W. C., Brueggemann, R. J., & Hope, W. (2022). Precision Therapy for Invasive Fungal Diseases. JOURNAL OF FUNGI, 8(1). doi:10.3390/jof8010018DOI: 10.3390/jof8010018
Rawson, T. M., Wilson, R. C., Moore, L. S. P., Macgowan, A. P., Lovering, A. M., Bayliss, M., . . . Holmes, A. H. (2021). Exploring the Pharmacokinetics of Phenoxymethylpenicillin (Penicillin-V) in Adults: A Healthy Volunteer Study. OPEN FORUM INFECTIOUS DISEASES, 8(12). doi:10.1093/ofid/ofab573DOI: 10.1093/ofid/ofab573
Optimizing antimicrobial use: challenges, advances and opportunities (Journal article)
Rawson, T. M., Wilson, R. C., O'Hare, D., Herrero, P., Kambugu, A., Lamorde, M., . . . Holmes, A. H. (2021). Optimizing antimicrobial use: challenges, advances and opportunities. NATURE REVIEWS MICROBIOLOGY, 19(12), 747-758. doi:10.1038/s41579-021-00578-9DOI: 10.1038/s41579-021-00578-9
Martson, A. -G., Sturkenboom, M. G. G., Knoester, M., van der Werf, T. S., Alffenaar, J. -W. C., Hope, W., & Consortium, G. S. (2021). Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(2), 466-473. doi:10.1093/jac/dkab419DOI: 10.1093/jac/dkab419
Nguyen, T. T. N., Nhat, T. H. L., Nguyen, N. V. V., Ninh, T. T. V., Nguyen, T. H. M., Duong, V. A., . . . Day, J. N. (2021). An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. ELIFE, 10. doi:10.7554/eLife.68929DOI: 10.7554/eLife.68929
Webb, E. L., Edielu, A., Wu, H. W., Kabatereine, N. B., Tukahebwa, E. M., Mubangizi, A., . . . Bustinduy, A. L. (2021). The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age. TRIALS, 22(1). doi:10.1186/s13063-021-05558-1DOI: 10.1186/s13063-021-05558-1
Stott, K. E., Loyse, A., Jarvis, J. N., Alufandika, M., Harrison, T. S., Mwandumba, H. C., . . . Hope, W. (2021). Cryptococcal meningoencephalitis: time for action. LANCET INFECTIOUS DISEASES, 21(9), E259-E271. doi:10.1016/S1473-3099(20)30771-4DOI: 10.1016/S1473-3099(20)30771-4
Darlow, C. A., da Costa, R. M. A., Ellis, S., Franceschi, F., Sharland, M., Piddock, L., . . . Hope, W. (2021). Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. PEDIATRIC DRUGS, 23(5), 465-484. doi:10.1007/s40272-021-00465-zDOI: 10.1007/s40272-021-00465-z
Sadouki, Z., McHugh, T. D., Aarnoutse, R., Canseco, J. O., Darlow, C., Hope, W., . . . Kloprogge, F. (2021). Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(9), 2252-2259. doi:10.1093/jac/dkab160DOI: 10.1093/jac/dkab160
Stott, K. E., Le, T., Nguyen, T., Whalley, S., Unsworth, J., Ly, V. T., . . . Hope, W. (2021). Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.. Antimicrobial agents and chemotherapy, 65(11), e0063621. doi:10.1128/aac.00636-21DOI: 10.1128/aac.00636-21
Charani, E., McKee, M., Ahmad, R., Balasegaram, M., Bonaconsa, C., Merrett, G. B., . . . Holmes, A. H. (2021). Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research. LANCET REGIONAL HEALTH-EUROPE, 7. doi:10.1016/j.lanepe.2021.100161DOI: 10.1016/j.lanepe.2021.100161
Darlow, C. A., Docobo-Perez, F., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., . . . Hope, W. (2021). Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00293-21DOI: 10.1128/aac.00293-21
Luque, S., Hope, W., Sorli, L., Munoz-Bermudez, R., Campillo, N., Barcelo-Vidal, J., . . . Grau, S. (2021). Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(6). doi:10.1128/AAC.02490-20DOI: 10.1128/AAC.02490-20
Kovanda, L. L., Sass, G., Martinez, M., Clemons, K. V., Nazik, H., Kitt, T. M., . . . Stevens, D. A. (2021). Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis.. Antimicrobial agents and chemotherapy, 65(6), e02344-e02320. doi:10.1128/aac.02344-20DOI: 10.1128/aac.02344-20
Merino-Bohorquez, V., Docobo-Perez, F., Valiente-Mendez, A., Delgado-Valverde, M., Camean, M., Hope, W. W., . . . Rodriguez-Bano, J. (2021). Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. ANTIBIOTICS-BASEL, 10(4). doi:10.3390/antibiotics10040348DOI: 10.3390/antibiotics10040348
Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy (Journal article)
Gastine, S., Hope, W., Hempel, G., Petraitiene, R., Petraitis, V., Mickiene, D., . . . Groll, A. H. (2021). Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.01574-20DOI: 10.1128/AAC.01574-20
Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models" (Journal article)
Das, S., Everett, M., Zalacain, M., & Hope, W. (2021). Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.02249-20DOI: 10.1128/AAC.02249-20
2020
FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development (Journal article)
Byrne, J. M., Waack, U., Weinstein, E. A., Joshi, A., Shurland, S. M., Iarikov, D., . . . Farley, J. J. (2021). FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(1). doi:10.1128/AAC.01983-20DOI: 10.1128/AAC.01983-20
Das, S., Fitzgerald, R., Ullah, A., Bula, M., Collins, A. M., Mitsi, E., . . . Hope, W. (2021). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(1). doi:10.1128/AAC.01468-20DOI: 10.1128/AAC.01468-20
Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae (Journal article)
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 64(11). doi:10.1128/AAC.01076-20DOI: 10.1128/AAC.01076-20
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. (Journal article)
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.. Antimicrob Agents Chemother, 64(11). doi:10.1128/AAC.01076-20DOI: 10.1128/AAC.01076-20
Boyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020). Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(10). doi:10.1128/AAC.00397-20DOI: 10.1128/AAC.00397-20
Bustinduy, A. L., Kolamunnage-Dona, R., Mirochnick, M. H., Capparelli, E. V., Tallo, V., Acosta, L. P., . . . Hope, W. W. (2020). Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum. Antimicrobial Agents and Chemotherapy, 64(9). doi:10.1128/AAC.00566-20DOI: 10.1128/AAC.00566-20
How to design a study to evaluate therapeutic drug monitoring in infectious diseases? (Journal article)
Martson, A. -G., Sturkenboom, M. G. G., Stojanova, J., Cattaneo, D., Hope, W., Marriott, D., . . . Alffenaar, J. -W. C. (2020). How to design a study to evaluate therapeutic drug monitoring in infectious diseases?. Clinical Microbiology and Infection, 26(8), 1008-1016. doi:10.1016/j.cmi.2020.03.008DOI: 10.1016/j.cmi.2020.03.008
Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review (Journal article)
McAleenan, A., Ambrose, P. G., Bhavnani, S. M., Drusano, G. L., Hope, W. W., Mouton, J. W., . . . MacGowan, A. P. (2020). Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(6), 1374-1389. doi:10.1093/jac/dkaa005DOI: 10.1093/jac/dkaa005
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i> (Journal article)
Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., . . . Hope, W. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(6). doi:10.1128/AAC.00180-20DOI: 10.1128/AAC.00180-20
Hill, L. F., Turner, M. A., Lutsar, I., Heath, P. T., Hardy, P., Linsell, L., . . . Sharland, M. (2020). An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-020-4184-8DOI: 10.1186/s13063-020-4184-8
Benitez-Cano, A., Luque, S., Sorli, L., Carazo, J., Ramos, I., Campillo, N., . . . Grau, S. (2020). Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. CRITICAL CARE, 24(1). doi:10.1186/s13054-020-2763-4DOI: 10.1186/s13054-020-2763-4
De Rycker, M., Horn, D., Aldridge, B., Amewu, R. K., Barry, C. E. I. I. I., Buckner, F. S., . . . Gilbert, I. H. (2020). Setting Our Sights on Infectious Diseases. ACS INFECTIOUS DISEASES, 6(1), 3-13. doi:10.1021/acsinfecdis.9b00371DOI: 10.1021/acsinfecdis.9b00371
2019
Hope, W., Stone, N. R. H., Johnson, A., McEntee, L., Farrington, N., Santoro-Castelazo, A., . . . Bicanic, T. (2019). Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.. mBio, 10(6). doi:10.1128/mbio.02575-19DOI: 10.1128/mbio.02575-19
Petraitis, V., Petraitiene, R., Valdez, J. M., Pyrgos, V., Lizak, M. J., Klaunberg, B. A., . . . Walsh, T. J. (2019). Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(12). doi:10.1128/AAC.01626-19DOI: 10.1128/AAC.01626-19
Avedissian, S. N., Pais, G. M., O'Donnell, J. N., Lodise, T. P., Liu, J., Prozialeck, W. C., . . . Scheetz, M. H. (2019). Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(8), 2326-2334. doi:10.1093/jac/dkz167DOI: 10.1093/jac/dkz167
Cojutti, P. G., Maximova, N., Schillani, G., Hope, W., & Pea, F. (2019). Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i>. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1648-1655. doi:10.1093/jac/dkz065DOI: 10.1093/jac/dkz065
Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., . . . Hoover, J. L. (2019). Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(5). doi:10.1128/AAC.02307-18DOI: 10.1128/aac.02307-18
Kovanda, L. L., Sullivan, S. M., Smith, L. R., Desai, A. V., Bonate, P. L., & Hope, W. W. (2019). Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.00163-19DOI: 10.1128/aac.00163-19
Blassmann, U., Hope, W., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., . . . Huge, V. (2019). CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(4), 991-996. doi:10.1093/jac/dky543DOI: 10.1093/jac/dky543
Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., . . . Bicanic, T. (2019). Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. JOURNAL OF CLINICAL INVESTIGATION, 129(3), 999-1014. doi:10.1172/JCI124516DOI: 10.1172/JCI124516
Le, T., Ly, V. T., Thu, N. T. M., Nguyen, A., Thanh, N. T., Vinh Chau, N. V., . . . Hope, W. (2019). Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. Antimicrobial Agents and Chemotherapy, 63(2). doi:10.1128/aac.01739-18DOI: 10.1128/aac.01739-18
Hope, W., Johnstone, G., Cicconi, S., Felton, T., Goodwin, J., Whalley, S., . . . Neely, M. (2019). Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.02353-18DOI: 10.1128/aac.02353-18
Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., . . . Harrison, T. S. (2019). Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 68(3), 393-401. doi:10.1093/cid/ciy515DOI: 10.1093/cid/ciy515
Lawrence, D. S., Youssouf, N., Molloy, S. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2019). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018). TRIALS, 20. doi:10.1186/s13063-018-3155-9DOI: 10.1186/s13063-018-3155-9
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., . . . Day, J. (2019). A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.. Wellcome open research, 4, 8. doi:10.12688/wellcomeopenres.15010.1DOI: 10.12688/wellcomeopenres.15010.1
Andes, D. R., Ghannoum, M. A., Mukherjee, P. K., Kovanda, L. L., Lu, Q., Jones, M. E., . . . Hope, W. W. (2019). Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(1). doi:10.1128/AAC.01634-18DOI: 10.1128/AAC.01634-18
Luque, S., Hope, W., Campillo, N., Munoz-Bermudez, R., Sorli, L., Barcelo-Vidal, J., . . . Grau, S. (2019). Population Pharmacokinetics of Anidulafungin in Critically III Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(7). doi:10.1128/AAC.00378-19DOI: 10.1128/aac.00378-19
Kovanda, L. L., Giamberardino, C., McEntee, L., Toffaletti, D. L., Franke, K. S., Bartuska, A., . . . Perfect, J. R. (2019). Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(9). doi:10.1128/AAC.00546-19DOI: 10.1128/AAC.00546-19
McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A., Jain, A., . . . Hope, W. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(8). doi:10.1128/AAC.00603-19DOI: 10.1128/aac.00603-19
2018
Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018) (Journal article)
Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Nguyen, T. H. M., Nguyen, L. N. T., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02249-18DOI: 10.1128/AAC.02249-18
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018) (Journal article)
Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Castelazo, A. S., Kibengo, F. M., Nguyen, T. H. M., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02254-18DOI: 10.1128/AAC.02254-18
Lawrence, D. S., Youssouf, N., Molloy, S. L. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2018). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. TRIALS, 19. doi:10.1186/s13063-018-3026-4DOI: 10.1186/s13063-018-3026-4
Cojutti, P. G., Candoni, A., Lazzarotto, D., Rabassi, N., Fanin, R., Hope, W., & Pea, F. (2018). Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(11), 2544-2550. doi:10.1111/bcp.13707DOI: 10.1111/bcp.13707
Merino-Bohorquez, V., Docobo-Perez, F., Sojo, J., Morales, I., Lupion, C., Martin, D., . . . Rodriguez-Bano, J. (2018). Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i>. CLINICAL MICROBIOLOGY AND INFECTION, 24(11), 1177-1183. doi:10.1016/j.cmi.2018.02.005DOI: 10.1016/j.cmi.2018.02.005
Cojutti, P. G., Lugano, M., Righi, E., Della Rocca, G., Bassetti, M., Hope, W., & Pea, F. (2018). Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non<i>-albicans</i> spp.. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(11), 1449-1459. doi:10.1007/s00228-018-2526-1DOI: 10.1007/s00228-018-2526-1
Benjamin, D. K. J., Kaufman, D. A., Hope, W. W., Smith, P. B., Arrieta, A., Manzoni, P., . . . Walsh, T. J. (2018). A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 37(10), 992-998. doi:10.1097/INF.0000000000001996DOI: 10.1097/inf.0000000000001996
Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Santoyo Castelazo, A., Kibengo, F. M., Mai, N. T. H., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 62(9). doi:10.1128/aac.00885-18DOI: 10.1128/aac.00885-18
Cojutti, P. G., Barbarino, C., De Monte, A., Hope, W., & Pea, F. (2018). Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(8), 1091-1092. doi:10.1007/s00228-018-2465-xDOI: 10.1007/s00228-018-2465-x
Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system (Journal article)
Stott, K. E., & Hope, W. (2018). Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(8), 803-815. doi:10.1080/17425255.2018.1492551DOI: 10.1080/17425255.2018.1492551
Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Mai, N. T. H., Tung, N. L. N., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. Antimicrobial agents and chemotherapy, 62(7). doi:10.1128/aac.02526-17DOI: 10.1128/aac.02526-17
Rawson, T. M., Charani, E., Moore, L. S. P., Gilchrist, M., Georgiou, P., Hope, W., & Holmes, A. H. (2018). Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. THERAPEUTIC DRUG MONITORING, 40(3), 315-321. doi:10.1097/FTD.0000000000000507DOI: 10.1097/ftd.0000000000000507
Felton, T. W., Ogungbenro, K., Boselli, E., Hope, W. W., & Rodvold, K. A. (2018). Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(5), 1340-1347. doi:10.1093/jac/dkx541DOI: 10.1093/jac/dkx541
Box, H., Negri, C., Livermore, J., Whalley, S., Johnson, A., McEntee, L., . . . Hope, W. (2018). Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(5). doi:10.1128/AAC.02516-17DOI: 10.1128/aac.02516-17
Rawson, T. M., O'Hare, D., Herrero, P., Sharma, S., Moore, L. S. P., de Barra, E., . . . Holmes, A. H. (2018). Delivering precision antimicrobial therapy through closed-loop control systems. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(4), 835-843. doi:10.1093/jac/dkx458DOI: 10.1093/jac/dkx458
Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., . . . Hope, W. W. (2018). Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.. The Journal of infectious diseases, 217(7), 1118-1127. doi:10.1093/infdis/jix479DOI: 10.1093/infdis/jix479
Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17DOI: 10.1128/aac.01909-17
Kontoyiannis, D. P., Selleslag, D., Mullane, K., Cornely, O. A., Hope, W., Lortholary, O., . . . Patterson, T. F. (2018). Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a <i>post hoc</i> analysis of the SECURE trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 757-763. doi:10.1093/jac/dkx423DOI: 10.1093/jac/dkx423
Torok, M. E., Aljayyoussi, G., Waterhouse, D., Chau, T. T. H., Mai, N. T. H., Phu, N. H., . . . Ward, S. A. (2018). Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral Therapy. CLINICAL PHARMACOLOGY & THERAPEUTICS, 103(3), 449-457. doi:10.1002/cpt.646DOI: 10.1002/cpt.646
Antifungal Dosing Considerations for Term and Preterm Infants (Chapter)
Lestner, J., & Hope, W. (2019). Antifungal Dosing Considerations for Term and Preterm Infants. In Infectious Disease and Pharmacology (pp. 185-191). Elsevier. doi:10.1016/b978-0-323-54391-0.00015-1DOI: 10.1016/b978-0-323-54391-0.00015-1
2017
Desai, A. V., Kovanda, L. L., Hope, W. W., Andes, D., Mouton, J. W., Kowalski, D. L., . . . Bonate, P. L. (2017). Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01034-17DOI: 10.1128/aac.01034-17
Ramos-Martin, V., Johnson, A., McEntee, L., Farrington, N., Padmore, K., Cojutti, P., . . . Hope, W. W. (2017). Pharmacodynamics of teicoplanin against MRSA. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(12), 3382-3389. doi:10.1093/jac/dkx289DOI: 10.1093/jac/dkx289
Schmitt-Hoffmann, A. -H., Kato, K., Townsend, R., Potchoiba, M. J., Hope, W. W., Andes, D., . . . Schneidkraut, M. J. (2017). Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01292-17DOI: 10.1128/AAC.01292-17
Rodvold, K. A., Hope, W. W., & Boyd, S. E. (2017). Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. CURRENT OPINION IN PHARMACOLOGY, 36, 114-123. doi:10.1016/j.coph.2017.09.019DOI: 10.1016/j.coph.2017.09.019
Petraitis, V., Petraitiene, R., McCarthy, M. W., Kovanda, L. L., Zaw, M. H., Hussain, K., . . . Walsh, T. J. (2017). Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9). doi:10.1128/AAC.00305-17DOI: 10.1128/aac.00305-17
Boyd, S. E., Moore, L. S. P., Rawson, T. M., Hope, W. W., & Holmes, A. H. (2017). Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al effect on resistance remains unclear. LANCET INFECTIOUS DISEASES, 17(9), 899-+. doi:10.1016/S1473-3099(17)30450-4DOI: 10.1016/S1473-3099(17)30450-4
Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., . . . Rex, J. H. (n.d.). Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.. mBio, 8(4). doi:10.1128/mbio.01157-17DOI: 10.1128/mbio.01157-17
Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E., Herrero, P., . . . Holmes, A. H. (2017). A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?. CLINICAL MICROBIOLOGY AND INFECTION, 23(8), 524-532. doi:10.1016/j.cmi.2017.02.028DOI: 10.1016/j.cmi.2017.02.028
Cojutti, P. G., Candoni, A., Ramos-Martin, V., lazzarotto, D., Zannier, M. E., Fanin, R., . . . Pea, F. (2017). Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(8), 2342-2350. doi:10.1093/jac/dkx140DOI: 10.1093/jac/dkx140
Petraitis, V., Petraitiene, R., Hope, W. W., & Walsh, T. J. (2017). Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.. Methods in molecular biology (Clifton, N.J.), 1625, 259-277. doi:10.1007/978-1-4939-7104-6_18DOI: 10.1007/978-1-4939-7104-6_18
Lestner, J., McEntee, L., Johnson, A., Livermore, J., Whalley, S., Schwartz, J., . . . Hope, W. (2017). Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.. Antimicrobial agents and chemotherapy, 61(06), 11 pages. doi:10.1128/aac.00090-17DOI: 10.1128/aac.00090-17
Kovanda, L. L., Marty, F. M., Maertens, J., Desai, A. V., Lademacher, C., Engelhardt, M., . . . Hope, W. W. (2017). Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6). doi:10.1128/AAC.00101-17DOI: 10.1128/AAC.00101-17
PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. (Journal article)
Hyatt, M. W., Wiederhold, N. P., Hope, W. W., & Stott, K. E. (2017). PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (<i>SPHENISCUS DEMERSUS</i>) AFTER SINGLE AND MULTIPLE DOSES. JOURNAL OF ZOO AND WILDLIFE MEDICINE, 48(2), 352-362. doi:10.1638/2016-0160R2.1DOI: 10.1638/2016-0160r2.1
Kovanda, L. L., Kolamunnage-Dona, R., Neely, M., Maertens, J., Misun, L., & Hope, W. (2017). Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clinical Infectious Diseases, 64(11), 1557-1563. doi:10.1093/cid/cix198DOI: 10.1093/cid/cix198
Li, G., Standing, J. F., Bielicki, J., Hope, W., van den Anker, J., Heath, P. T., & Sharland, M. (2017). The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. DRUGS, 77(9), 941-950. doi:10.1007/s40265-017-0745-xDOI: 10.1007/s40265-017-0745-x
Kovanda, L. L., Desai, A. V., & Hope, W. W. (2017). Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 44(2), 143-151. doi:10.1007/s10928-017-9509-1DOI: 10.1007/s10928-017-9509-1
Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function (Journal article)
Cojutti, P. G., Ramos-Martin, V., Schiavon, I., Rossi, P., Baraldo, M., Hope, W., & Pea, F. (2017). Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(3). doi:10.1128/AAC.02134-16DOI: 10.1128/AAC.02134-16
Stott, K. E., & Hope, W. W. (2017). Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72, I12-I18. doi:10.1093/jac/dkx029DOI: 10.1093/jac/dkx029
Rawson, T. M., Charani, E., Moore, L. S. P., Herrero, P., Baik, J. S., Philip, A., . . . Holmes, A. H. (2017). Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. JOURNAL OF INFECTION, 74(3), 320-324. doi:10.1016/j.jinf.2016.12.011DOI: 10.1016/j.jinf.2016.12.011
Seibel, N. L., Shad, A. T., Bekersky, I., Groll, A. H., Gonzalez, C., Wood, L. V., . . . Walsh, T. J. (2017). Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(2). doi:10.1128/AAC.01477-16DOI: 10.1128/AAC.01477-16
Haloprogin (Chapter)
Ramos-Martín, V., & Hope, W. (2017). Haloprogin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2933-2935). doi:10.1201/9781315152110DOI: 10.1201/9781315152110
Sime, F. B., Johnson, A., Whalley, S., Santoyo-Castelazo, A., Montgomery, A. B., Walters, K. A., . . . Roberts, J. A. (2017). Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01763-16DOI: 10.1128/AAC.01763-16
Ramos-Martin, V., Neely, M. N., Padmore, K., Peak, M., Beresford, M. W., Turner, M. A., . . . Hope, W. W. (2017). Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(10). doi:10.1128/AAC.00707-17DOI: 10.1128/aac.00707-17
2016
Lestner, J. M., Groll, A. H., Aljayyoussi, G., Seibel, N. L., Shad, A., Gonzalez, C., . . . Hope, W. W. (2016). Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(12), 7340-7346. doi:10.1128/AAC.01427-16DOI: 10.1128/AAC.01427-16
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., . . . Birch, M. (2016). F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(45), 12809-12814. doi:10.1073/pnas.1608304113DOI: 10.1073/pnas.1608304113
Hope, W., Drusano, G. L., & Rex, J. H. (2016). Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(11), 3008-3019. doi:10.1093/jac/dkw298DOI: 10.1093/jac/dkw298
Ramos-Martín, V., Neely, M. N., McGowan, P., Siner, S., Padmore, K., Peak, M., . . . Hope, W. W. (2016). Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.. The Journal of antimicrobial chemotherapy, 71(11), 3168-3178. doi:10.1093/jac/dkw295DOI: 10.1093/jac/dkw295
Blassmann, U., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., Hope, W., . . . Huge, V. (2016). Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. CRITICAL CARE, 20. doi:10.1186/s13054-016-1523-yDOI: 10.1186/s13054-016-1523-y
Bustinduy, A. L., Waterhouse, D., de Sousa-Figueiredo, J. C., Roberts, S. A., Atuhaire, A., Van Dam, G. J., . . . Stothard, J. R. (2016). Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. mBio, 7(4). doi:10.1128/mBio.00227-16DOI: 10.1128/mBio.00227-16
Kovanda, L. L., Desai, A. V., Lu, Q., Townsend, R. W., Akhtar, S., Bonate, P., & Hope, W. W. (2016). Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4568-4576. doi:10.1128/AAC.00514-16DOI: 10.1128/AAC.00514-16
Hope, W. W., Walsh, T. J., Goodwin, J., Peloquin, C. A., Howard, A., Kurtzberg, J., . . . Wingard, J. R. (2016). Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(8), 2234-2240. doi:10.1093/jac/dkw127DOI: 10.1093/jac/dkw127
Kovanda, L. L., Maher, R., & Hope, W. W. (2016). Isavuconazonium sulfate: A new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Review of Clinical Pharmacology, 9(7), 887-897. doi:10.1080/17512433.2016.1185361DOI: 10.1080/17512433.2016.1185361
Kovanda, L. L., Petraitiene, R., Petraitis, V., Walsh, T. J., Desai, A., Bonate, P., & Hope, W. W. (2016). Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1885-1891. doi:10.1093/jac/dkw098DOI: 10.1093/jac/dkw098
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis (Journal article)
Petraitis, V., Petraitiene, R., Moradi, P. W., Strauss, G. E., Katragkou, A., Kovanda, L. L., . . . Walsh, T. J. (2016). Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(5), 2718-2726. doi:10.1128/AAC.02665-15DOI: 10.1128/AAC.02665-15
Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy (Journal article)
Huurneman, L. J., Neely, M., Veringa, A., Docobo Perez, F., Ramos-Martin, V., Tissing, W. J., . . . Hope, W. (2016). Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2336-2342. doi:10.1128/AAC.03023-15DOI: 10.1128/AAC.03023-15
Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates (Journal article)
Ramos-Martin, V., Johnson, A., Livermore, J., McEntee, L., Goodwin, J., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 71(4), 992-1002. doi:10.1093/jac/dkv451DOI: 10.1093/jac/dkv451
Liposomal Amphotericin B (AmBisome<SUP>®</SUP>): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions (Journal article)
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016). Liposomal Amphotericin B (AmBisome<SUP>®</SUP>): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. DRUGS, 76(4), 485-500. doi:10.1007/s40265-016-0538-7DOI: 10.1007/s40265-016-0538-7
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial (Journal article)
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., . . . Ullmann, A. J. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet, 387(10020), 760-769. doi:10.1016/S0140-6736(15)01159-9DOI: 10.1016/S0140-6736(15)01159-9
Antifungal Pharmacokinetics and Pharmacodynamics (Chapter)
Hope, W., & Andes, D. R. (2016). Antifungal Pharmacokinetics and Pharmacodynamics. In Methods in Pharmacology and Toxicology (pp. 369-383). Springer New York. doi:10.1007/978-1-4939-3323-5_15DOI: 10.1007/978-1-4939-3323-5_15
Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis (Journal article)
Box, H., Livermore, J., Johnson, A., McEntee, L., Felton, T. W., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 278-287. doi:10.1128/AAC.01364-15DOI: 10.1128/AAC.01364-15
2015
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1 (Journal article)
Drusano, G. L., Louie, A., MacGowan, A., & Hope, W. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1183-1193. doi:10.1128/AAC.02177-15DOI: 10.1128/AAC.02177-15
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2 (Journal article)
Drusano, G. L., Hope, W., MacGowan, A., & Louie, A. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1194-1201. doi:10.1128/AAC.02231-15DOI: 10.1128/AAC.02231-15
Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits (Journal article)
Petraitiene, R., Petraitis, V., Hope, W. W., & Walsh, T. J. (2015). Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. CLINICAL INFECTIOUS DISEASES, 61, S643-S651. doi:10.1093/cid/civ817DOI: 10.1093/cid/civ817
Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? (Journal article)
Huttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3178-3183. doi:10.1093/jac/dkv201DOI: 10.1093/jac/dkv201
Clinical pharmacology of antifungal agents in pediatrics: children are not small adults (Journal article)
Ramos-Martin, V., O'Connor, O., & Hope, W. (2015). Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. CURRENT OPINION IN PHARMACOLOGY, 24, 128-134. doi:10.1016/j.coph.2015.08.009DOI: 10.1016/j.coph.2015.08.009
Linezolid underexposure in a patient co-treated with venlafaxine (Journal article)
Cojutti, P., Crapis, M., Bassetti, M., Hope, W., & Pea, F. (2015). Linezolid underexposure in a patient co-treated with venlafaxine. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 71(10), 1285-1286. doi:10.1007/s00228-015-1922-zDOI: 10.1007/s00228-015-1922-z
Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis (Journal article)
Grau, S., Luque, S., Campillo, N., Samso, E., Rodriguez, U., Garcia-Bernedo, C. A., . . . Roberts, J. A. (2015). Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2854-2861. doi:10.1093/jac/dkv173DOI: 10.1093/jac/dkv173
Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance (Journal article)
Docobo-Perez, F., Drusano, G. L., Johnson, A., Goodwin, J., Whalley, S., Ramos-Martin, V., . . . Hope, W. W. (2015). Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(9), 5602-5610. doi:10.1128/AAC.00752-15DOI: 10.1128/AAC.00752-15
AMBITION-<i>cm</i>: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial (Journal article)
Molefi, M., Chofle, A. A., Molloy, S. F., Kalluvya, S., Changalucha, J. M., Cainelli, F., . . . Jarvis, J. N. (2015). AMBITION-<i>cm</i>: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. TRIALS, 16. doi:10.1186/s13063-015-0799-6DOI: 10.1186/s13063-015-0799-6
Achieving target voriconazole concentrations more accurately in children and adolescents (Journal article)
Neely, M., Margol, A., Fu, X., van Guilder, M., Bayard, D., Schumitzky, A., . . . Hope, W. (2015). Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrobial Agents and Chemotherapy, 59(6), 3090-3097. doi:10.1128/AAC.00032-15DOI: 10.1128/AAC.00032-15
Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i> (Journal article)
Al-Nakeeb, Z., Petraitis, V., Goodwin, J., Petraitiene, R., Walsh, T. J., & Hope, W. W. (2015). Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(5), 2735-2745. doi:10.1128/AAC.04723-14DOI: 10.1128/AAC.04723-14
Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients (Journal article)
Roberts, J. A., Udy, A. A., Jarrett, P., Wallis, S. C., Hope, W. W., Sharma, R., . . . Lipman, J. (2015). Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(5), 1495-1502. doi:10.1093/jac/dku564DOI: 10.1093/jac/dku564
Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients (Journal article)
Wong, G., Farkas, A., Sussman, R., Daroczi, G., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(3), 1411-1417. doi:10.1128/AAC.04001-14DOI: 10.1128/AAC.04001-14
Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents (Journal article)
Hope, W. W., Kaibara, A., Roy, M., Arrieta, A., Azie, N., Kovanda, L. L., & Benjamin, D. K. J. (2015). Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(2), 905-913. doi:10.1128/AAC.03736-14DOI: 10.1128/AAC.03736-14
Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development (Journal article)
Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Hope, W. W., & Roberts, J. A. (2015). Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 36(1), 136-153. doi:10.1055/s-0034-1398490DOI: 10.1055/s-0034-1398490
Guidelines need controls (Journal article)
Raoult, D., Hope, W., & Kahlmeter, G. (2015). Guidelines need controls. CLINICAL MICROBIOLOGY AND INFECTION, 21(12), 1043-1044. doi:10.1016/j.cmi.2015.09.010DOI: 10.1016/j.cmi.2015.09.010
2014
First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole (Journal article)
Zhao, W., Le Guellec, C., Benjamin, D. K. J., Hope, W. W., Bourgeois, T., Watt, K. M., . . . Jacqz-Aigrain, E. (2014). First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. CLINICAL PHARMACOKINETICS, 53(11), 1005-1018. doi:10.1007/s40262-014-0169-7DOI: 10.1007/s40262-014-0169-7
Population Pharmacokinetics of Teicoplanin in Children (Journal article)
Ramos-Martin, V., Paulus, S., Siner, S., Scott, E., Padmore, K., Newland, P., . . . Hope, W. W. (2014). Population Pharmacokinetics of Teicoplanin in Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(11), 6920-6927. doi:10.1128/AAC.03685-14DOI: 10.1128/AAC.03685-14
Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients (Journal article)
Felton, T. W., McCalman, K., Malagon, I., Isalska, B., Whalley, S., Goodwin, J., . . . Hope, W. W. (2014). Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. Clinical Pharmacology & Therapeutics, 96(4), 438-448. doi:10.1038/clpt.2014.131DOI: 10.1038/clpt.2014.131
Gene Expression Profiles of Human Dendritic Cells Interacting with <i>Aspergillus fumigatus</i> in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface (Journal article)
Morton, C. O., Fliesser, M., Dittrich, M., Mueller, T., Bauer, R., Kneitz, S., . . . Loeffler, J. (2014). Gene Expression Profiles of Human Dendritic Cells Interacting with <i>Aspergillus fumigatus</i> in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface. PLOS ONE, 9(5). doi:10.1371/journal.pone.0098279DOI: 10.1371/journal.pone.0098279
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology (Journal article)
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014). Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(5), 1162-1176. doi:10.1093/jac/dkt508DOI: 10.1093/jac/dkt508
An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance (Journal article)
Gomez-Lopez, A., Forastiero, A., Cendejas-Bueno, E., Gregson, L., Mellado, E., Howard, S. J., . . . Cuenca-Estrella, M. (2014). An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance. MEDICAL MYCOLOGY, 52(3), 311-319. doi:10.1093/mmy/myt022DOI: 10.1093/mmy/myt022
Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units (Journal article)
Aliaga, S., Clark, R. H., Laughon, M., Walsh, T. J., Hope, W. W., Benjamin, D. K., . . . Smith, P. B. (2014). Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units. PEDIATRICS, 133(2), 236-242. doi:10.1542/peds.2013-0671DOI: 10.1542/peds.2013-0671
Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days (Journal article)
Livermore, J., Howard, S. J., Sharp, A. D., Goodwin, J., Gregson, L., Felton, T., . . . Hope, W. (2014). Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. mBio, 5(1). doi:10.1128/mBio.00725-13DOI: 10.1128/mBio.00725-13
Tissue Penetration of Antifungal Agents (Journal article)
Felton, T., Troke, P. F., & Hope, W. W. (2014). Tissue Penetration of Antifungal Agents. CLINICAL MICROBIOLOGY REVIEWS, 27(1), 68-88. doi:10.1128/CMR.00046-13DOI: 10.1128/CMR.00046-13
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi (Journal article)
Chowdhary, A., Meis, J. F., Guarro, J., de Hoog, G. S., Kathuria, S., Arendrup, M. C., . . . Cuenca-Estrella, M. (2014). ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. CLINICAL MICROBIOLOGY AND INFECTION, 20, 47-75. doi:10.1111/1469-0691.12515DOI: 10.1111/1469-0691.12515
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others (Journal article)
Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., . . . Lass-Floerl, C. (2014). ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. CLINICAL MICROBIOLOGY AND INFECTION, 20, 27-46. doi:10.1111/1469-0691.12465DOI: 10.1111/1469-0691.12465
ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of mucormycosis 2013 (Journal article)
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., . . . Petrikkos, G. (2014). ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of mucormycosis 2013. CLINICAL MICROBIOLOGY AND INFECTION, 20, 5-26. doi:10.1111/1469-0691.12371DOI: 10.1111/1469-0691.12371
ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of rare invasive yeast infections (Journal article)
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014). ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. CLINICAL MICROBIOLOGY AND INFECTION, 20, 76-98. doi:10.1111/1469-0691.12360DOI: 10.1111/1469-0691.12360
EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole (Journal article)
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2014). EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole. MYCOSES, 57(6), 377-379. doi:10.1111/myc.12170DOI: 10.1111/myc.12170
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation (Journal article)
Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J. -H., Engelhard, D., Hope, W., . . . Lehrnbecher, T. (2014). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. LANCET ONCOLOGY, 15(8), E327-E340. doi:10.1016/S1470-2045(14)70017-8DOI: 10.1016/S1470-2045(14)70017-8
How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? (Journal article)
Felton, T. W., Hope, W. W., & Roberts, J. A. (2014). How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 79(4), 441-447. doi:10.1016/j.diagmicrobio.2014.04.007DOI: 10.1016/j.diagmicrobio.2014.04.007
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions (Journal article)
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., . . . Kuti, J. L. (2014). Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. LANCET INFECTIOUS DISEASES, 14(6), 498-509. doi:10.1016/S1473-3099(14)70036-2DOI: 10.1016/S1473-3099(14)70036-2
Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy (Journal article)
Felton, T. W., Roberts, J. A., Lodise, T. P., Van Guilder, M., Boselli, E., Neely, M. N., & Hope, W. W. (2014). Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(7), 4094-4102. doi:10.1128/AAC.02664-14DOI: 10.1128/AAC.02664-14
2013
Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> (Journal article)
Felton, T. W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., . . . Hope, W. W. (2013). Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 5811-5819. doi:10.1128/AAC.00867-13DOI: 10.1128/AAC.00867-13
<i>In Vitro</i> Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole (Journal article)
Gregson, L., Goodwin, J., Johnson, A., McEntee, L., Moore, C. B., Richardson, M., . . . Howard, S. J. (2013). <i>In Vitro</i> Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5778-5780. doi:10.1128/AAC.01141-13DOI: 10.1128/AAC.01141-13
Invasive fungal infections (Journal article)
Hope, W., Natarajan, P., & Goodwin, L. (2013). Invasive fungal infections. CLINICAL MEDICINE, 13(5), 507-510. doi:10.7861/clinmedicine.13-5-507DOI: 10.7861/clinmedicine.13-5-507
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: the pharmacometrics of infectious disease.. CPT: pharmacometrics & systems pharmacology, 2, e70. doi:10.1038/psp.2013.46DOI: 10.1038/psp.2013.46
Opinion: The Pharmacometrics of Infectious Disease (Journal article)
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics & Systems Pharmacology, 2(8), 1-3. doi:10.1038/psp.2013.46DOI: 10.1038/psp.2013.46
Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients (Journal article)
O'Connor, L., Livermore, J., Sharp, A. D., Goodwin, J., Gregson, L., Howard, S. J., . . . Hope, W. W. (2013). Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. JOURNAL OF INFECTIOUS DISEASES, 208(2), 351-361. doi:10.1093/infdis/jit164DOI: 10.1093/infdis/jit164
Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections (Journal article)
Lestner, J., & Hope, W. W. (2013). Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 9(7), 911-926. doi:10.1517/17425255.2013.794785DOI: 10.1517/17425255.2013.794785
Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective (Journal article)
Lestner, J. M., Smith, P. B., Cohen-Wolkowiez, M., Benjamin, D. K. J., & Hope, W. W. (2013). Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75(6), 1381-1395. doi:10.1111/bcp.12025DOI: 10.1111/bcp.12025
Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints (Journal article)
Sudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(6), 2793-2800. doi:10.1128/AAC.00216-13DOI: 10.1128/AAC.00216-13
Software for Dosage Individualization of Voriconazole for Immunocompromised Patients (Journal article)
Hope, W. W., VanGuilder, M., Donnelly, J. P., Blijlevens, N. M. A., Bruggemann, R. J. M., Jelliffe, R. W., & Neely, M. N. (2013). Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(4), 1888-1894. doi:10.1128/AAC.02025-12DOI: 10.1128/AAC.02025-12
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp. (Journal article)
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.. DRUG RESISTANCE UPDATES, 16(6), 81-95. doi:10.1016/j.drup.2014.01.001DOI: 10.1016/j.drup.2014.01.001
EUCAST Technical Note on Voriconazole and Aspergillus spp. (Journal article)
Hope, W. W., Cuenca-Estrella, M., Lass-Floerl, C., & Arendrup, M. C. (2013). EUCAST Technical Note on Voriconazole and Aspergillus spp.. CLINICAL MICROBIOLOGY AND INFECTION, 19(6), E278-E280. doi:10.1111/1469-0691.12148DOI: 10.1111/1469-0691.12148
Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection (Journal article)
Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(1), 281-288. doi:10.1128/AAC.01387-12DOI: 10.1128/AAC.01387-12
The pharmacometrics of infectious diseases (Journal article)
Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46
2012
Optimizing Micafungin Dosing in Children (Journal article)
Zhao, W., Hope, W. W., Manzoni, P., & Jacqz-Aigrain, E. (2012). Optimizing Micafungin Dosing in Children. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 31(11), 1211-1212. doi:10.1097/INF.0b013e3182624bacDOI: 10.1097/INF.0b013e3182624bac
Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant <i>Aspergillus fumigatus</i> in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis (Journal article)
Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Warn, P. A., & Hope, W. W. (2012). Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant <i>Aspergillus fumigatus</i> in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5180-5185. doi:10.1128/AAC.01111-12DOI: 10.1128/AAC.01111-12
Isolation of <i>Aspergillus</i> species from the airway of lung transplant recipients is associated with excess mortality (Journal article)
Felton, T. W., Roberts, S. A., Isalska, B., Brennan, S., Philips, A., Whiteside, S., . . . Hope, W. W. (2012). Isolation of <i>Aspergillus</i> species from the airway of lung transplant recipients is associated with excess mortality. JOURNAL OF INFECTION, 65(4), 350-356. doi:10.1016/j.jinf.2012.07.008DOI: 10.1016/j.jinf.2012.07.008
Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens (Journal article)
Hope, W. W., Goodwin, J., Felton, T. W., Ellis, M., & Stevens, D. A. (2012). Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5303-5308. doi:10.1128/AAC.00933-12DOI: 10.1128/AAC.00933-12
Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012) (Journal article)
Alastruey-Izquierdo, A., Gomez-Lopez, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012). JOURNAL OF CLINICAL MICROBIOLOGY, 50(9), 3149. doi:10.1128/JCM.01843-12DOI: 10.1128/JCM.01843-12
Pharmacodynamics of Itraconazole against <i>Aspergillus fumigatus</i> in an <i>In</i> <i>Vitro</i> Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration (Journal article)
Al-Nakeeb, Z., Sudan, A., Jeans, A. R., Gregson, L., Goodwin, J., Warn, P. A., . . . Hope, W. W. (2012). Pharmacodynamics of Itraconazole against <i>Aspergillus fumigatus</i> in an <i>In</i> <i>Vitro</i> Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4146-4153. doi:10.1128/AAC.00141-12DOI: 10.1128/AAC.00141-12
Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints (Journal article)
Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Majithiya, J. B., . . . Hope, W. W. (2012). Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints. JOURNAL OF INFECTIOUS DISEASES, 206(3), 442-452. doi:10.1093/infdis/jis372DOI: 10.1093/infdis/jis372
Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections (Journal article)
Felton, T. W., Hope, W. W., Lomaestro, B. M., Butterfield, J. M., Kwa, A. L., Drusano, G. L., & Lodise, T. P. (2012). Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4087-4094. doi:10.1128/AAC.00521-12DOI: 10.1128/AAC.00521-12
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. (Journal article)
Alastruey-Izquierdo, A., Gómez-López, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.. Journal of clinical microbiology, 50(7), 2509-2512. doi:10.1128/jcm.00791-12DOI: 10.1128/jcm.00791-12
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections (Journal article)
Livermore, J., & Hope, W. (2012). Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 8(6), 759-765. doi:10.1517/17425255.2012.683859DOI: 10.1517/17425255.2012.683859
Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without <i>FKS</i> Resistance Mutations (Journal article)
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012). Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without <i>FKS</i> Resistance Mutations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(5), 2435-2442. doi:10.1128/AAC.06369-11DOI: 10.1128/AAC.06369-11
Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions (Journal article)
Hope, W. W., Howard, S. J., & Felton, T. W. (2012). Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. MYCOSES, 55, 33-38. doi:10.1111/j.1439-0507.2011.02114.xDOI: 10.1111/j.1439-0507.2011.02114.x
Posaconazole: The Case for Therapeutic Drug Monitoring (Journal article)
Howard, S. J., Felton, T. W., Gomez-Lopez, A., & Hope, W. W. (2012). Posaconazole: The Case for Therapeutic Drug Monitoring. THERAPEUTIC DRUG MONITORING, 34(1), 72-76. doi:10.1097/FTD.0b013e31823cdeacDOI: 10.1097/FTD.0b013e31823cdeac
Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach (Journal article)
Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., . . . Hope, W. W. (2012). Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 708-714. doi:10.1128/AAC.05826-11DOI: 10.1128/AAC.05826-11
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) (Journal article)
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., . . . Cuenca-Estrella, M. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). CLINICAL MICROBIOLOGY AND INFECTION, 18, 53-67. doi:10.1111/1469-0691.12041DOI: 10.1111/1469-0691.12041
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases (Journal article)
Ullmann, A. J., Cornely, O. A., Donnelly, J. P., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., . . . Cuenca-Estrella, M. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. CLINICAL MICROBIOLOGY AND INFECTION, 18, 1-8. doi:10.1111/1469-0691.12037DOI: 10.1111/1469-0691.12037
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures (Journal article)
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. CLINICAL MICROBIOLOGY AND INFECTION, 18, 9-18. doi:10.1111/1469-0691.12038DOI: 10.1111/1469-0691.12038
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients (Journal article)
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. CLINICAL MICROBIOLOGY AND INFECTION, 18, 19-37. doi:10.1111/1469-0691.12039DOI: 10.1111/1469-0691.12039
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS (Journal article)
Lortholary, O., Petrikkos, G., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. CLINICAL MICROBIOLOGY AND INFECTION, 18, 68-77. doi:10.1111/1469-0691.12042DOI: 10.1111/1469-0691.12042
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. (Journal article)
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. CLINICAL MICROBIOLOGY AND INFECTION, 18, 38-52. doi:10.1111/1469-0691.12040DOI: 10.1111/1469-0691.12040
EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole (Journal article)
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floel, C., & Hope, W. W. (2012). EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E248-E250. doi:10.1111/j.1469-0691.2012.03890.xDOI: 10.1111/j.1469-0691.2012.03890.x
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST) (Journal article)
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. (2012). EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E246-E247. doi:10.1111/j.1469-0691.2012.03880.xDOI: 10.1111/j.1469-0691.2012.03880.x
In vitro model of invasive pulmonary aspergillosis in the human alveolus. (Journal article)
Gregson, L., Hope, W. W., & Howard, S. J. (2012). In vitro model of invasive pulmonary aspergillosis in the human alveolus.. Methods in molecular biology (Clifton, N.J.), 845, 361-367. doi:10.1007/978-1-61779-539-8_24DOI: 10.1007/978-1-61779-539-8_24
Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. (Journal article)
Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2012). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.. Antimicrob Agents Chemother..
Population Pharmacokinetics of Voriconazole in Adults (Journal article)
Hope, W. W. (2012). Population Pharmacokinetics of Voriconazole in Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(1), 526-531. doi:10.1128/AAC.00702-11DOI: 10.1128/AAC.00702-11
2011
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011) (Journal article)
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(11), 5415. doi:10.1128/AAC.05771-11DOI: 10.1128/AAC.05771-11
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (Journal article)
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4782-4788. doi:10.1128/AAC.01083-10DOI: 10.1128/AAC.01083-10
Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts (Journal article)
Howard, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4880-4887. doi:10.1128/AAC.00621-11DOI: 10.1128/AAC.00621-11
Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis? (Journal article)
Rodriguez-Tudela, J. L., Hope, W., Cuenca-Estrella, M., Donnelly, J. P., Lass-Flörl, C., & Arendrup, M. C. (2011). Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 5(3), 128-134. doi:10.1007/s12281-011-0058-6DOI: 10.1007/s12281-011-0058-6
Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin (Journal article)
Slater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(7), 3075-3083. doi:10.1128/AAC.01686-10DOI: 10.1128/AAC.01686-10
Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy (Journal article)
Howard, S. J., Lestner, J. M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., . . . Hope, W. W. (2011). Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. JOURNAL OF INFECTIOUS DISEASES, 203(9), 1324-1332. doi:10.1093/infdis/jir023DOI: 10.1093/infdis/jir023
Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates (Journal article)
Cohen-Wolkowiez, M., Benjamin, D. K. J., Piper, L., Cheifetz, I. M., Moran, C., Liu, P., . . . Smith, P. B. (2011). Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates. CLINICAL PHARMACOLOGY & THERAPEUTICS, 89(5), 702-707. doi:10.1038/clpt.2011.26DOI: 10.1038/clpt.2011.26
EUCAST Technical note on Amphotericin B (Journal article)
Lass-Floerl, C., Arendrup, M. C., Rodriguez-Tudela, J. -L., Cuenca-Estrella, M., Donnelly, P., & Hope, W. (2011). EUCAST Technical note on Amphotericin B. CLINICAL MICROBIOLOGY AND INFECTION, 17(12), E27-E29. doi:10.1111/j.1469-0691.2011.03644.xDOI: 10.1111/j.1469-0691.2011.03644.x
EUCAST technical note on anidulafungin (Journal article)
Arendrup, M. C., Rodriguez-Tudela, J. -L., Lass-Floerl, C., Cuenca-Estrella, M., Donnelly, J. P., & Hope, W. (2011). EUCAST technical note on anidulafungin. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E18-E20. doi:10.1111/j.1469-0691.2011.03647.xDOI: 10.1111/j.1469-0691.2011.03647.x
EUCAST technical note on posaconazole (Journal article)
Arendrup, M. C., Cuenca-Estrella, M., Donnelly, J. P., Hope, W., Lass-Floerl, C., & Rodriguez-Tudela, J. -L. (2011). EUCAST technical note on posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E16-E17. doi:10.1111/j.1469-0691.2011.03646.xDOI: 10.1111/j.1469-0691.2011.03646.x
Fluconazole Loading Dose Pharmacokinetics and Safety in Infants (Journal article)
Piper, L., Smith, P. B., Hornik, C. P., Cheifetz, I. M., Barrett, J. S., Moorthy, G., . . . Benjamin, D. K. J. (2011). Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 30(5), 375-378. doi:10.1097/INF.0b013e318202cbb3DOI: 10.1097/INF.0b013e318202cbb3
Innate immunity in human newborn infants: prematurity means more than immaturity. (Journal article)
Strunk, T., Currie, A., Richmond, P., Simmer, K., & Burgner, D. (2011). Innate immunity in human newborn infants: prematurity means more than immaturity.. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 24(1), 25-31. doi:10.3109/14767058.2010.482605DOI: 10.3109/14767058.2010.482605
Optimizing management of invasive mould diseases (Journal article)
Agrawal, S., Hope, W., Sinko, J., & Kibbler, C. (2011). Optimizing management of invasive mould diseases. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66, i45-i53. doi:10.1093/jac/dkq441DOI: 10.1093/jac/dkq441
Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy. (Journal article)
Stefanidis, D., Hope, W. W., & Scott, D. J. (2011). Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy.. Surgical endoscopy, 25(7), 2141-2146. doi:10.1007/s00464-010-1512-1DOI: 10.1007/s00464-010-1512-1
The management of <i>Candida</i> infections in preterm neonates and the role of micafungin (Journal article)
Manzoni, P., Benjamin, D. K., Hope, W., Rizzollo, S., Del Sordo, P., Stronati, M., . . . Farina, D. (2011). The management of <i>Candida</i> infections in preterm neonates and the role of micafungin. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 24, 25-28. doi:10.3109/14767058.2011.604929DOI: 10.3109/14767058.2011.604929
2010
Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis (Journal article)
Felton, T. W., Baxter, C., Moore, C. B., Roberts, S. A., Hope, W. W., & Denning, D. W. (2010). Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. CLINICAL INFECTIOUS DISEASES, 51(12), 1383-1391. doi:10.1086/657306DOI: 10.1086/657306
The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-D-Glucan, and Consequences of Delayed Antifungal Therapy (Journal article)
Hope, W. W., Petraitis, V., Petraitiene, R., Aghamolla, T., Bacher, J., & Walsh, T. J. (2010). The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-D-Glucan, and Consequences of Delayed Antifungal Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(11), 4879-4886. doi:10.1128/AAC.00673-10DOI: 10.1128/AAC.00673-10
Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis (Journal article)
Lestner, J. M., Howard, S. J., Goodwin, J., Gregson, L., Majithiya, J., Walsh, T. J., . . . Hope, W. W. (2010). Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3432-3441. doi:10.1128/AAC.01586-09DOI: 10.1128/AAC.01586-09
Population Pharmacokinetics of Micafungin in Neonates and Young Infants (Journal article)
Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., . . . Benjamin, D. K. J. (2010). Population Pharmacokinetics of Micafungin in Neonates and Young Infants. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2633-2637. doi:10.1128/AAC.01679-09DOI: 10.1128/AAC.01679-09
Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential? (Journal article)
Roberts, J. A., Hope, W. W., & Lipman, J. (2010). Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 35(5), 419-420. doi:10.1016/j.ijantimicag.2010.01.022DOI: 10.1016/j.ijantimicag.2010.01.022
Therapy for fungal diseases: opportunities and priorities (Journal article)
Denning, D. W., & Hope, W. W. (2010). Therapy for fungal diseases: opportunities and priorities. TRENDS IN MICROBIOLOGY, 18(5), 195-204. doi:10.1016/j.tim.2010.02.004DOI: 10.1016/j.tim.2010.02.004
Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis (Chapter)
Howard, S. J., & Hope, W. W. (2010). Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis. In ASPERGILLOSIS: FROM DIAGNOSIS TO PREVENTION (pp. 217-228). doi:10.1007/978-90-481-2408-4_14DOI: 10.1007/978-90-481-2408-4_14
Echinocandins (Chapter)
Perlin, D. S., & Hope, W. W. (2010). Echinocandins. In ASPERGILLOSIS: FROM DIAGNOSIS TO PREVENTION (pp. 263-279). doi:10.1007/978-90-481-2408-4_16DOI: 10.1007/978-90-481-2408-4_16
Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants (Journal article)
Benjamin, D. K. J., Smith, P. B., Arrieta, A., Castro, L., Sanchez, P. J., Kaufman, D., . . . Walsh, T. J. (2010). Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. CLINICAL PHARMACOLOGY & THERAPEUTICS, 87(1), 93-99. doi:10.1038/clpt.2009.200DOI: 10.1038/clpt.2009.200
2009
Aspergillus (Chapter)
Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology (pp. 271-296). Elsevier. doi:10.1016/b978-1-4160-5680-5.00011-6DOI: 10.1016/b978-1-4160-5680-5.00011-6
Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring (Journal article)
Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009). Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. CLINICAL INFECTIOUS DISEASES, 49(6), 928-930. doi:10.1086/605499DOI: 10.1086/605499
Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis (Journal article)
Hope, W. W. (2009). Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. MEDICAL MYCOLOGY, 47, S291-S298. doi:10.1080/13693780802510232DOI: 10.1080/13693780802510232
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect (Journal article)
Warn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., & Hope, W. W. (2009). Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(8), 3453-3461. doi:10.1128/AAC.01601-08DOI: 10.1128/AAC.01601-08
<i>Rational Testing</i> Assessing candiduria in a critically ill patient (Journal article)
Hope, W. W. (2009). <i>Rational Testing</i> Assessing candiduria in a critically ill patient. BRITISH MEDICAL JOURNAL, 338. doi:10.1136/bmj.b2289DOI: 10.1136/bmj.b2289
Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis (Journal article)
Petraitis, V., Petraitiene, R., Hope, W. W., Meletiadis, J., Mickiene, D., Hughes, J. E., . . . Walsh, T. J. (2009). Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(6), 2382-2391. doi:10.1128/AAC.00329-09DOI: 10.1128/AAC.00329-09
Aspergillus (Chapter)
Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology with CD-ROM (pp. 271-296). doi:10.1016/B978-1-4160-5680-5/00011-6DOI: 10.1016/B978-1-4160-5680-5/00011-6
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside (Journal article)
Hope, W. W., & Drusano, G. L. (2009). Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. CLINICAL MICROBIOLOGY AND INFECTION, 15(7), 602-612. doi:10.1111/j.1469-0691.2009.02913.xDOI: 10.1111/j.1469-0691.2009.02913.x
Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates (Journal article)
Smith, P. B., Walsh, T. J., Hope, W., Arrieta, A., Takada, A., Kovanda, L. L., . . . Benjamin, D. K. J. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 28(5), 412-415. doi:10.1097/INF.0b013e3181910e2dDOI: 10.1097/INF.0b013e3181910e2d
2008
Therapeutic drug monitoring for triazoles (Journal article)
Hope, W. W., Billaud, E. M., Lestner, J., & Denning, D. W. (2008). Therapeutic drug monitoring for triazoles. CURRENT OPINION IN INFECTIOUS DISEASES, 21(6), 580-586. doi:10.1097/QCO.0b013e3283184611DOI: 10.1097/QCO.0b013e3283184611
Cerebrospinal Fluid and Plasma (1→3)-β-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis (Journal article)
Petraitiene, R., Petraitis, V., Hope, W. W., Mickiene, D., Kelaher, A. M., Murray, H. A., . . . Walsh, T. J. (2008). Cerebrospinal Fluid and Plasma (1→3)-β-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4121-4129. doi:10.1128/AAC.00674-08DOI: 10.1128/AAC.00674-08
Interactions of <i>Aspergillus</i> with the Mucosa (Chapter)
Hope, W. W., & Filler, S. G. (n.d.). Interactions of <i>Aspergillus</i> with the Mucosa. In <i>Aspergillus fumigatus</i> and Aspergillosis (pp. 239-245). ASM Press. doi:10.1128/9781555815523.ch19DOI: 10.1128/9781555815523.ch19
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (Journal article)
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., . . . Bennett, J. E. (2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. CLINICAL INFECTIOUS DISEASES, 46(12), 1813-1821. doi:10.1086/588660DOI: 10.1086/588660
Experimental Design Considerations in Pharmacokinetic Studies (Chapter)
Hope, W. W., Petraitis, V., & Walsh, T. J. (2008). Experimental Design Considerations in Pharmacokinetic Studies. In Unknown Book (pp. 1059-1068). Wiley. doi:10.1002/9780470249031.ch31DOI: 10.1002/9780470249031.ch31
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous <i>Candida</i> meningoencephalitis:: Implications for echinocandin therapy in neonates (Journal article)
Hope, W. W., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A. M., Hughes, J. E., . . . Walsh, T. J. (2008). The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous <i>Candida</i> meningoencephalitis:: Implications for echinocandin therapy in neonates. JOURNAL OF INFECTIOUS DISEASES, 197(1), 163-171. doi:10.1086/524063DOI: 10.1086/524063
2007
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing (Journal article)
Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2007). Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3760-3762. doi:10.1128/AAC.00488-07DOI: 10.1128/AAC.00488-07
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing (Journal article)
Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A., Flynn, P., Shad, A., . . . Walsh, T. J. (2007). Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3714-3719. doi:10.1128/AAC.00398-07DOI: 10.1128/AAC.00398-07
The pharmacology and clinical use of caspofungin (Journal article)
Hope, W. W., Shoham, S., & Walsh, T. J. (2007). The pharmacology and clinical use of caspofungin. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 3(2), 263-274. doi:10.1517/17425255.3.2.263DOI: 10.1517/17425255.3.2.263
Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:: Implications for antifungal therapy (Journal article)
Hope, W. W., Kruhlak, M. J., Lyman, C. A., Petraitiene, R., Petraitis, V., Francesconi, A., . . . Walsh, T. J. (2007). Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:: Implications for antifungal therapy. JOURNAL OF INFECTIOUS DISEASES, 195(3), 455-466. doi:10.1086/510535DOI: 10.1086/510535
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis (Journal article)
Hope, W. W., Drusano, G. L., Moore, C. B., Sharp, A., Louie, A., Walsh, T. J., . . . Warn, P. A. (2007). Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(1), 285-295. doi:10.1128/AAC.00601-06DOI: 10.1128/AAC.00601-06
Galactomannan antigen detection in the diagnosis of invasive aspergillosis (Journal article)
Verdaguer, V., Walsh, T. J., Hope, W., & Cortez, K. J. (2007). Galactomannan antigen detection in the diagnosis of invasive aspergillosis. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 7(1), 21-32. doi:10.1586/14737159.7.1.21DOI: 10.1586/14737159.7.1.21
2006
Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and impact of the MIC, growth rate, and resistance genotype on the antifungal effect (Journal article)
Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., . . . Denning, D. W. (2006). Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(11), 3680-3688. doi:10.1128/AAC.00369-06DOI: 10.1128/AAC.00369-06
Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt (Journal article)
Anaissie, E. J., Segal, B. H., Graybill, J. R., Arndt, C., Perfect, J. R., Kleinberg, M., . . . Zaoutis, T. (2006). Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt. CLINICAL INFECTIOUS DISEASES, 43(8), 1031-1039. doi:10.1086/509116DOI: 10.1086/509116
Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis (Journal article)
Francesconi, A., Kasai, M., Petraitiene, R., Petraitis, V., Kelaher, A. M., Schaufele, R., . . . Walsh, T. J. (2006). Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. JOURNAL OF CLINICAL MICROBIOLOGY, 44(7), 2475-2480. doi:10.1128/JCM.02693-05DOI: 10.1128/JCM.02693-05
2005
Laboratory diagnosis of invasive aspergillosis (Journal article)
Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). Laboratory diagnosis of invasive aspergillosis. LANCET INFECTIOUS DISEASES, 5(10), 609-622. doi:10.1016/S1473-3099(05)70238-3DOI: 10.1016/S1473-3099(05)70238-3
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis (Journal article)
Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2005). Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. JOURNAL OF INFECTIOUS DISEASES, 192(4), 673-680. doi:10.1086/432069DOI: 10.1086/432069
The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp. (Journal article)
Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp.. MEDICAL MYCOLOGY, 43, S207-S238. doi:10.1080/13693780400025179DOI: 10.1080/13693780400025179
2004
Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i> (Journal article)
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004). Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 48(11), 4377-4386. doi:10.1128/AAC.48.11.4377-4386.2004DOI: 10.1128/AAC.48.11.4377-4386.2004
Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens (Journal article)
Hope, W. W., Padwell, A., Guiver, M., & Denning, D. W. (2004). Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. JOURNAL OF INFECTION, 49(2), 136-140. doi:10.1016/j.jinf.2004.02.008DOI: 10.1016/j.jinf.2004.02.008
Optimising antifungal therapy for individual patients (Journal article)
Hope, W. W., & Denning, D. W. (2004). Optimising antifungal therapy for individual patients. INTERNAL MEDICINE JOURNAL, 34(4), 147-149. doi:10.1111/j.1444-0903.2004.00569.xDOI: 10.1111/j.1444-0903.2004.00569.x
A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs (Journal article)
Hope, W. W., Morton, A. P., Looke, D. F. M., Schooneveldt, J. M., & Nimmo, G. R. (2004). A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs. PATHOLOGY, 36(3), 265-268. doi:10.1080/00313020410001692530DOI: 10.1080/00313020410001692530
Invasive aspergillosis: current and future challenges in diagnosis and therapy (Journal article)
Hope, W. W., & Denning, D. W. (2004). Invasive aspergillosis: current and future challenges in diagnosis and therapy. CLINICAL MICROBIOLOGY AND INFECTION, 10(1), 2-4. doi:10.1111/j.1469-0691.2004.00809.xDOI: 10.1111/j.1469-0691.2004.00809.x
2003
Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host (Journal article)
Hope, W., & Looke, D. (2003). Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host. JOURNAL OF INFECTION, 47(3), 256-259. doi:10.1016/S0163-4453(03)00083-5DOI: 10.1016/S0163-4453(03)00083-5
2002
A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida (Journal article)
Hope, W. W., Flohr, G., & Nimmo, G. R. (2002). A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida. Clinical Microbiology Newsletter, 24(18), 140-141. doi:10.1016/s0196-4399(02)80036-8DOI: 10.1016/s0196-4399(02)80036-8
Eisen, D. P., Bartley, P. B., Hope, W., Sigmundsdottir, G., Pehrson, C., Larsson, L., & Christensson, B. (2002). Urine D-arabinitol/L-arabinitol ratio in diagnosing <i>Candida</i> infection in patients with haematological malignancy and HIV infection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 42(1), 39-42. doi:10.1016/S0732-8893(01)00310-8DOI: 10.1016/S0732-8893(01)00310-8
Increase in prevalence of nosocomial non-<i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use (Journal article)
Hope, W., Morton, A., & Eisen, D. P. (2002). Increase in prevalence of nosocomial non-<i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use. JOURNAL OF HOSPITAL INFECTION, 50(1), 56-65. doi:10.1053/jhin.2001.1131DOI: 10.1053/jhin.2001.1131